These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12902615)

  • 1. Participation of the mineralocorticoid receptor in cardiac and vascular remodeling.
    Fiebeler A; Haller H
    Nephron Physiol; 2003; 94(3):p47-50. PubMed ID: 12902615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms.
    Chen D; Chen Z; Park C; Centrella M; McCarthy T; Chen L; Al-Omari A; Moeckel GW
    Gene; 2013 Nov; 531(1):23-30. PubMed ID: 23994292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease.
    Parker BM; Wertz SL; Pollard CM; Desimine VL; Maning J; McCrink KA; Lymperopoulos A
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone in vascular and metabolic dysfunction.
    Luther JM
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):16-21. PubMed ID: 26575396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions.
    Grossmann C; Benesic A; Krug AW; Freudinger R; Mildenberger S; Gassner B; Gekle M
    Mol Endocrinol; 2005 Jul; 19(7):1697-710. PubMed ID: 15761031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
    Bauersachs J; Jaisser F; Toto R
    Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
    Rafiq K; Hitomi H; Nakano D; Nishiyama A
    J Pharmacol Sci; 2011; 115(1):1-7. PubMed ID: 21186336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nongenomic actions of aldosterone.
    Funder JW
    Endocr Rev; 2005 May; 26(3):313-21. PubMed ID: 15814845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells.
    Mazak I; Fiebeler A; Muller DN; Park JK; Shagdarsuren E; Lindschau C; Dechend R; Viedt C; Pilz B; Haller H; Luft FC
    Circulation; 2004 Jun; 109(22):2792-800. PubMed ID: 15159288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?
    Bender SB; McGraw AP; Jaffe IZ; Sowers JR
    Diabetes; 2013 Feb; 62(2):313-9. PubMed ID: 23349535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying rapid aldosterone effects in the kidney.
    Thomas W; Harvey BJ
    Annu Rev Physiol; 2011; 73():335-57. PubMed ID: 20809792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
    Funder JW
    Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of mineralocorticoid action.
    Fuller PJ; Young MJ
    Hypertension; 2005 Dec; 46(6):1227-35. PubMed ID: 16286565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone and its blockade: a cardiovascular and renal perspective.
    Lahera V; Cachofeiro V; Balfagon G; Rodicio JL
    ScientificWorldJournal; 2006 Apr; 6():413-24. PubMed ID: 16604252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone and inflammation.
    Gilbert KC; Brown NJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):199-204. PubMed ID: 20422780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone and end-organ damage.
    Brown NJ
    Curr Opin Nephrol Hypertens; 2005 May; 14(3):235-41. PubMed ID: 15821416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of aldosterone.
    Murin J
    Bratisl Lek Listy; 2005; 106(1):3-19. PubMed ID: 15869008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes.
    Tsai CF; Yang SF; Chu HJ; Ueng KC
    Int J Cardiol; 2013 Oct; 169(1):17-28. PubMed ID: 24120080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid-related signaling effects in vascular smooth muscle cells.
    Molnar GA; Lindschau C; Dubrovska G; Mertens PR; Kirsch T; Quinkler M; Gollasch M; Wresche S; Luft FC; Muller DN; Fiebeler A
    Hypertension; 2008 May; 51(5):1372-8. PubMed ID: 18347231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.